Zach Klaassen· @zklaassen_md · X·· 2 天前评分70
正文 · 原文
Updated results from Ph 1b/2 KEYNOTE-365 Cohort I: Pembro + Chemo (n=40) vs Chemo (n=30) for NEPC @urotoday #ESMO26
Pembro + Chemo vs Chemo:
📌ORR: 28% vs 15%
📌DCR: 50% vs 48%
📌Med DOR: 6.2 vs 4.1 mos
📌m-rPFS: 5.1 vs 4.0 mos; HR 0.66, 95%CI 0.36-1.21
📌mOS: 10.2 vs 7.1 mos; HR 0.33, 95%CI 0.17-0.63
180 浏览 · 3 赞 · 2 转发 · 0 回复
会议摘要
Updated results from the phase 1b/2 KEYNOTE-365 cohort I: Pembrolizumab (pembro) + carboplatin and etoposide chemotherapy (chemo) or chemo alone for neuroendocrine prostate cancer (NEPC)
https://esmocongress.esmo.org来源：Zach Klaassen · x.com